I'm a member
You will be redirected to myBlue. Would you like to continue?
Please wait while you are redirected.
Please enter a username and password.
Printer Friendly Version
Photodynamic therapy (PDT) refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Photosensitizing agents, administered orally or intravenously, have been used in nondermatologic applications and are being proposed for use with dermatologic conditions such as actinic keratoses and non-melanoma skin cancers.
Two common photosenitizing agents are 5-aminolevulinic acid (5-ALA) and its methyl ester, methyl aminolevulinate (MAL). When applied topically, these agents pass readily through abnormal keratin overlying the lesion and accumulate preferentially in dysplastic cells. 5-ALA and MAL are metabolized by underlying cells to photosensitizing concentrations of porphyrins. Subsequent exposure to photoactivation (maximum absorption at 404-420 nm and 635 nm, respectively) generates reactive oxygen species that are cytotoxic, ultimately destroying the lesion. PDT can cause erythema, burning, and pain. Healing occurs within 10 to 14 days, with generally acceptable cosmetic results. PDT with topical ALA has been investigated primarily as a treatment of actinic keratoses. It has also been investigated as a treatment of other superficial dermatologic lesions, such as Bowen’s disease, acne vulgaris, mycoses, hidradenitis suppurativa, and superficial and nodular basal cell carcinoma (BCC). Potential cosmetic indications include skin rejuvenation and hair removal.
Actinic keratoses are rough, scaly, or warty premaligant growths on sun-exposed skin that are very common in older individuals with fair complexions, with a prevalence of greater than 80% in fair-skinned people over the age of 60. In some cases, actinic keratosis may progress to squamous cell carcinoma (SCC). Available treatments for actinic keratoses can be divided into surgical and non-surgical methods. Surgical treatments used to treat one or a small number of dispersed individual lesions include excision, curettage (either alone or combined with electrodesiccation), and laser surgery. Non-surgical treatments include cryotherapy, topical chemotherapy (5-fluorouracil [5-FU] or masoprocol creams), chemexfoliation (chemical peels), and dermabrasion. Topical treatments are generally used in patients with multiple lesions and involve extensive areas of skin. Under some circumstances, combinations treatments may be used.
Non-melanoma skin cancers are the most common malignancies in the Caucasian population. Basal cell carcinoma (BCC) is most often found in light-skinned individuals and is the most common of the cutaneous malignancies. Although BCC tumors rarely metastasize, they can be locally invasive if left untreated, leading to significant local destruction and disfigurement. The most prevalent forms of BCC are nodular BCC and superficial BCC. Bowen disease is a squamous cell carcinoma (SCC) in situ with the potential for significant lateral spread. Metastases are rare, with less than 5% of cases advancing to invasive SCC. Lesions may appear on sun-exposed or covered skin. Excision surgery is the preferred treatment for smaller non-melanoma skin lesions and those not in problematic areas, such as the face and digits. Other established treatments include topical 5-fluorouracil, imiquimod, and cryotherapy. Poor cosmesis resulting from surgical procedures and skin irritation induced by topical agents can be significant problems.
In 1999, Levulan® KerastickTM, a topical preparation of ALA, in conjunction with illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator, received approval by the U.S. Food and Drug Administration (FDA) for the following indication:
"The Levulan Kerastick for topical solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp." The product is applied in the physician's office.
A 5-aminolevulinic acid patch technology (5-ALA Patch) is available outside of the U.S through an agreement between Intendis (part of Bayer HealthCare) and Photonamic. The 5-ALA patch is not approved by FDA.
Another variant of photodynamic therapy (PDT) for skin lesions is Metvixia® used with the Aktilite CL128 lamp, each of which received FDA approval in 2004. Metvixia® (Galderma, Switzerland; Photocure, Norway) consists of the topical application of methyl aminolevulinate (in contrast to ALA used in the Kerastick procedure), followed by exposure with the Aktilite CL 128 lamp, a red light source (in contrast to the blue light source in the Kerastick procedure). Broadband light sources (containing the appropriate wavelengths), intense pulsed light (IPL), pulsed dye lasers (PDL), and potassium titanyl phosphate (KTP) lasers have also been used. Metvixia is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used with lesion preparation (debridement using a sharp dermal curette) in the physician's office when other therapies are unacceptable or considered medically less appropriate.
POLICYPhotodynamic therapy may be considered medically necessary as a treatment of:
Photodynamic therapy is considered investigational for other dermatologic applications, including, but not limited to, acne vulgaris, high-risk basal cell carcinomas, hidradenitis suppurativa, and mycoses.
Photodynamic therapy as a technique of skin rejuvenation, hair removal, or other cosmetic indications is considered not medically necessary.
POLICY EXCEPTIONSFederal Employee Program (FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Surgery and radiation is the preferred treatments for low-risk basal cell cancer and Bowen disease. If photodynamic therapy is selected for these indications because of contraindications to surgery or radiation, patients and physicians need to be aware that it may have a lower cure rate in comparison with surgery or radiation.
Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Nervous/Mental Conditions, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:
A. consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and
B. appropriate with regard to standards of good medical practice; and
C. not solely for the convenience of the Member, his or her Provider; and
D. the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.
For the definition of Medically Necessary, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary.
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
POLICY HISTORY8/2001: Approved by Medical Policy Advisory Committee (MPAC)
11/14/2001: Hyperlink inserted
1/23/2002: "Sources", "Type of Service", and "Place of Service" sections updated; Noncovered codes added
2/14/2002: Investigational definition added
5/2/2002: Type of Service and Place of Service deleted
5/28/2002: Code Reference section updated
3/25/2004: Reviewed by MPAC, remains investigational, Description section aligned with BCBSA policy # 2.01.44, FEP exception added, Sources updated
5/19/2004: Coding reviewed, no changes
7/15/2005: Policy reviewed by MPAC, Description section updated to include verbiage for acne vulgaris and other skin related conditions. Policy section updated to indicate that photodynamic therapy with topical ALA and exposure to blue and red light and photodynamic therapy with methyl aminolevulinate and exposure to red light are considered investigational for acne vulgaris and other skin related conditions. Photodynamic therapy for cosmetic indications is not considered medically necessary. Policy titled "Photodynamic Therapy (PDT) for Actinic Keratoses (AKs)" renamed "Photodynamic Therapy."
10/17/2005: Code Reference table reviewed, diagnosis code 702.0 deleted
8/3/2007: Policy reviewed, description updated to include BCC and change Metvix to Metvixia®. Policy title "Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions" renamed "Dermatologic Applications of Photodynamic Therapy." Policy statement revised: Non-hyperkeratotic actinic keratoses, superficial BCC, and Bowen's disease changed from investigational to may be considered medically necessary; non-superficial BCC is considered investigational. CPT 96567, ICD-9 procedure code 99.83, and HCPCS J7308 moved to covered with note to see POLICY. Added ICD-9 codes173.0-173.9, 232.0-232.9, and 702.0 with note to see POLICY.
11/15/2007: Policy revisions approved by MPAC
8/21/2008: Policy reviewed, no changes
9/28/2009: Verbiage, "* Some covered procedure codes may have multiple descriptions. Coverage will only be made for covered codes when used for services outlined within the policy statement section." added to Coding Section.
04/23/2010: Policy description and guidelines updated regarding treatment approaches. Policy statement unchanged. FEP verbiage added to the Policy Exceptions section. Deleted outdated references from the Sources section.
08/03/2010: Policy description updated to add Metvixia® and the Aktilite CL128 lamp as an approved variant of PDT for skin lesions. Policy statement unchanged. Added HCPCS code J3490 for reporting Metvixia®.
03/07/2011: Added new HCPCS code J7309 for reporting Metvixia® and deleted J3490. Added ICD-9 codes 209.31-209.36 to the Code Reference section.
02/24/2012: Policy reviewed; no changes.
04/03/2013: Policy reviewed; no changes.
03/11/2014: Policy reviewed; no changes.
02/12/2015: Policy reviewed; description updated. Medically necessary policy statement updated to change "Superficial basal cell skin cancer" to "Low-risk (eg superficial and nodular) basal cell skin cancer." Investigational statement revised to change "non-superficial basal cell carcinomas" to "high-risk basal cell carcinomas." Policy guidelines updated to change "superficial basal cell cancer" to "low-risk basal cell cancer."
08/25/2015: Code Reference section updated for ICD-10.
03/07/2016: Policy reviewed; no change in policy statements. Policy guidelines updated to add medically necessary and investigative definitions.
06/01/2016: Policy number A.2.01.44 added.
12/21/2016: Policy reviewed; no changes.
SOURCE(S)Blue Cross Blue Shield Association policy # 2.01.44
CODE REFERENCEThis may not be a comprehensive list of procedure codes applicable to this policy.
The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.
CPT copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.